Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients

Dissection of T-cell Antigen Specificity in Human Melanoma

(2012) R. S. Andersen et al.   CANCER RESEARCH

International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk?

(2012) Friederike Erdmann et al.   INTERNATIONAL JOURNAL OF CANCER

Myeloid-derived Suppressor Cells in Cancer Patients

(2012) Alberto J. Montero et al.   JOURNAL OF IMMUNOTHERAPY

Cancer immunotherapy

(2012) Thomas F. Gajewski   Molecular Oncology

Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers

(2012) Rikke Sick Andersen et al.   Nature Protocols

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients

(2012) Pia Kvistborg et al.   OncoImmunology

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells

(2011) S. Solito et al.   BLOOD

Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients

(2011) J. A. Kyte et al.   CLINICAL CANCER RESEARCH

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

(2011) J. M. Kirkwood et al.   CLINICAL CANCER RESEARCH

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

Regulatory T Cells

(2010) Tatiana N. Golovina et al.   CANCER JOURNAL

Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma

(2010) Steven E. Finkelstein et al.   JOURNAL OF IMMUNOTHERAPY

Long-Term Survival in Patients with Metastatic Melanoma Treated with DTIC or Temozolomide

(2010) C. Kim et al.   ONCOLOGIST

Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer

(2009) Andrew J. Rech et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

(2009) R. K. Amaravadi et al.   CLINICAL CANCER RESEARCH

The safety of temozolomide in the treatment of malignancies

(2009) Van Anh Trinh et al.   Expert Opinion On Drug Safety

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

(2009) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers

(2009) Sine Reker Hadrup et al.   NATURE METHODS

CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells

(2008) M. Kleinewietfeld et al.   BLOOD

A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma

(2008) Ahmad A. Tarhini et al.   CANCER

Phase II Study of Extended-Dose Temozolomide in Patients With Melanoma

(2008) Petra Rietschel et al.   JOURNAL OF CLINICAL ONCOLOGY

Transient T cell depletion causes regression of melanoma metastases

(2008) Mary Rasku et al.   Journal of Translational Medicine